Home
Epizyme

Epizyme Market Share Analysis for November 2025

epizyme is a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer

Health > Biotechnology and Pharmaceuticals

Domainepizyme.com

Year Founded2007

Employees201 - 500

Annual Revenue$25M - $50M

Epizyme

Epizyme (including company regionals)

epizyme.com

See more website traffic and engagement information

Epizyme Revenue up to November 2025 is 25M - 50M

revenue generated by Epizyme top domains

Epizyme top domains revenue over 3 years

Revenue for Epizyme top domains

epizyme.com25M - 50M

See more with Sales Intelligence

Total visits to Epizyme's top domains

Understand Epizyme market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Epizyme's top domains

Analyze Epizyme engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Epizyme's top domains

See how Epizyme keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Epizyme top competitors by domain

Top similar sites in November 2025, ranked by their affinity

agios.comCompany NameAgiosEmployees201 - 500HQUnited States, Massachusetts, CambridgeAnnual revenue$200M - $500MTotal visits15.8KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Epizyme

These are the website technologies, by industry, used by Epizyme top domains

Payment & Currencies (5)

Euro

Widget (4)

Google Maps

Social (3)

Google+ Platform

Advertising (2)

DoubleClick

More Technologies

9

See all

News & Signals from Epizyme

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsClementiapharma acquired Epizyme on Dec 5th '22.Most recently, Clementiapharma acquired the biotech Epizyme.

NewsEpizyme received financing of $79.8M in initial public offering on Jun 1st '13.Epizyme raised $79.8 million in an initial public offering in June 2013.